DENTSPLY SIRONA Inc (NASDAQ:XRAY) SVP Maureen J. Macinnis sold 54,402 shares of DENTSPLY SIRONA stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $55.00, for a total transaction of $2,992,110.00. Following the sale, the senior vice president now owns 50,962 shares of the company’s stock, valued at $2,802,910. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of DENTSPLY SIRONA stock opened at $54.87 on Wednesday. The stock has a market capitalization of $12.84 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 2.05 and a beta of 1.11. DENTSPLY SIRONA Inc has a fifty-two week low of $33.93 and a fifty-two week high of $55.88. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.06 and a quick ratio of 1.27.
DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. The business had revenue of $946.20 million during the quarter, compared to the consensus estimate of $925.13 million. DENTSPLY SIRONA had a negative net margin of 26.48% and a positive return on equity of 8.99%. The company’s revenue was down 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 earnings per share. On average, sell-side analysts predict that DENTSPLY SIRONA Inc will post 2.34 earnings per share for the current year.
Several equities research analysts have recently commented on the stock. BidaskClub downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. ValuEngine upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Barrington Research upgraded shares of DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $63.00 target price for the company in a research report on Monday, May 6th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. Finally, HC Wainwright restated a “neutral” rating and set a $55.00 target price (up from $49.00) on shares of DENTSPLY SIRONA in a research report on Monday, May 6th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. DENTSPLY SIRONA currently has a consensus rating of “Buy” and an average target price of $53.65.
WARNING: “DENTSPLY SIRONA Inc (XRAY) SVP Maureen J. Macinnis Sells 54,402 Shares” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/15/dentsply-sirona-inc-xray-svp-maureen-j-macinnis-sells-54402-shares.html.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Featured Article: Stock Selection – What is cash flow?
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.